$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000139047824000004 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Gross Profit		$0.00	$0.00
YoY Change			-100.0%
Gross Profit Margin
Selling, General & Admin	$4.534M	$3.080M	$13.86M
YoY Change	10.4%	-14.44%	10.17%
% of Gross Profit
Research & Development	$5.111M	$5.097M	$24.01M
YoY Change	-28.76%	-12.81%	18.45%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$9.645M	$8.177M	$37.87M
YoY Change	-14.5%	-13.43%	15.28%
Operating Profit	-$9.645M	-$8.177M	-$37.87M
YoY Change	-14.5%	-13.43%	-9.73%
Interest Expense		$41.00K	$525.0K
YoY Change		-74.05%	65.62%
% of Operating Profit
Other Income/Expense, Net	$79.00K	$0.00	$4.000K
YoY Change	3850.0%	-100.0%	-99.38%
Pretax Income		-$8.136M	-$37.34M
YoY Change		-10.8%	-9.59%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$9.600M	-$8.136M	-$37.34M
YoY Change	-13.51%	-10.8%	-9.59%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.21		-$1.34
Diluted Earnings Per Share	-$0.21	-$0.26	-$1.34
COMMON SHARES
Basic Shares Outstanding	56.27M shares	32.06M shares	27.78M shares
Diluted Shares Outstanding	44.81M shares		27.78M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.42M	$2.530M	$2.530M
YoY Change	-22.96%	-85.23%	-85.23%
Cash & Equivalents	$18.40M	$2.530M	$2.530M
Short-Term Investments
Other Short-Term Assets	$3.086M	$642.0K	$642.0K
YoY Change	45.57%	1.74%	1.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$21.50M	$3.172M	$3.172M
YoY Change	-17.37%	-82.14%	-82.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$747.0K	$858.0K	$858.0K
YoY Change	-4.72%	-1.83%	-1.83%
Goodwill	$1.914M	$1.900M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$272.0K	$275.0K	$275.0K
YoY Change	-29.17%	-31.08%	-31.08%
Total Long-Term Assets	$2.933M	$3.047M	$3.047M
YoY Change	-4.83%	-4.39%	-4.39%
TOTAL ASSETS
Total Short-Term Assets	$21.50M	$3.172M	$3.172M
Total Long-Term Assets	$2.933M	$3.047M	$3.047M
Total Assets	$24.43M	$6.219M	$6.219M
YoY Change	-16.05%	-70.31%	-70.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.407M	$5.639M	$5.639M
YoY Change	139.01%	67.98%	67.98%
Accrued Expenses	$6.542M	$8.054M	$8.054M
YoY Change	0.88%	28.13%	20.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$14.44M	$13.74M	$13.74M
YoY Change	-6.92%	-11.47%	-11.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$313.0K	$460.0K	$460.0K
YoY Change	-26.18%	-20.28%	-20.28%
Total Long-Term Liabilities	$313.0K	$460.0K	$460.0K
YoY Change	-26.18%	-20.28%	-20.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.44M	$13.74M	$13.74M
Total Long-Term Liabilities	$313.0K	$460.0K	$460.0K
Total Liabilities	$14.75M	$14.20M	$14.20M
YoY Change	-7.44%	-11.79%	-11.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$226.8M	-$217.2M
YoY Change	18.74%	20.73%
Common Stock	$236.5M	$209.3M
YoY Change	15.83%	13.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.684M	-$7.976M	-$7.976M
YoY Change
Total Liabilities & Shareholders Equity	$24.43M	$6.219M	$6.219M
YoY Change	-16.05%	-70.31%	-70.31%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$9.600M	-$8.136M	-$37.34M
YoY Change	-13.51%	-10.8%	-9.59%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$10.80M	-$4.820M	-$31.41M
YoY Change	-10.74%	-6.44%	31.97%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$5.500M
YoY Change			22.22%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	-$5.500M
YoY Change			22.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$22.35M
YoY Change			2032.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$26.65M	3.385M	22.32M
YoY Change	40.95%	264.37%	-7.33%
NET CHANGE
Cash From Operating Activities	-$10.80M	-4.820M	-31.41M
Cash From Investing Activities		0.000	-5.500M
Cash From Financing Activities	$26.65M	3.385M	22.32M
Net Change In Cash	$15.89M	-1.435M	-14.60M
YoY Change	134.4%	-66.02%	245.04%
FREE CASH FLOW
Cash From Operating Activities	-$10.80M	-$4.820M	-$31.41M
Capital Expenditures		$0.00	$5.500M
Free Cash Flow		-$4.820M	-$36.91M
YoY Change		-6.44%	30.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	858000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1914000	usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2503
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2023	dei	City Area Code CityAreaCode	(646)
CY2023	dei	Local Phone Number LocalPhoneNumber	200-5278
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2530000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	542000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7650000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	446000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13735000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	460000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	16092000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21005405	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	184753000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-179904000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4851000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20943000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1000000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	20268000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12582000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	107000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2094000	usd
CY2023	sls	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	4000	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13862000	usd
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	10000000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	42950000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.3151
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M4D
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	44401259	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56267670	shares
CY2023	dei	Auditor Firm AuditorFirmId	659
CY2023	dei	Auditor Name AuditorName	Moss Adams LLP
CY2023	dei	Auditor Location AuditorLocation	Campbell, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17125000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3172000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	17756000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	874000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1914000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	275000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	399000	usd
CY2023Q4	us-gaap	Assets Assets	6219000	usd
CY2022Q4	us-gaap	Assets Assets	20943000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5639000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3357000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6286000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	372000	usd
CY2023Q4	sls	Acquired In Process Research And Development Payable Current AcquiredInProcessResearchAndDevelopmentPayableCurrent	0	usd
CY2022Q4	sls	Acquired In Process Research And Development Payable Current AcquiredInProcessResearchAndDevelopmentPayableCurrent	5500000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15515000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	573000	usd
CY2023Q4	sls	Fair Value Of Warrant Liability Potentially Settleable In Cash FairValueOfWarrantLiabilityPotentiallySettleableInCash	0	usd
CY2022Q4	sls	Fair Value Of Warrant Liability Potentially Settleable In Cash FairValueOfWarrantLiabilityPotentiallySettleableInCash	4000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14195000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32132890	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32132890	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21005405	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	209265000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-217244000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7976000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6219000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	24007000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	37869000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-37869000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-41950000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-36000	usd
CY2023	sls	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	0	usd
CY2022	sls	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	296000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	525000	usd
CY2022	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	317000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	529000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	649000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37340000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-41301000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.13
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27777111	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19395709	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20347000	usd
CY2022	sls	Stock Issued During Period Value Common Stockand Warrants StockIssuedDuringPeriodValueCommonStockandWarrants	22946000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1048000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	85000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1726000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-41301000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4851000	usd
CY2023	sls	Stock Issued During Period Value Common Stockand Warrants StockIssuedDuringPeriodValueCommonStockandWarrants	22040000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	289000	usd
CY2023	sls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	14000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	31000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2094000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2094000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37340000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-7976000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37340000	usd
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	10000000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1726000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	495000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	457000	usd
CY2023	sls	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	0	usd
CY2022	sls	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	296000	usd
CY2022	sls	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	36000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-113000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1253000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2301000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1213000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1449000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3646000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-518000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-471000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31410000	usd
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	5500000	usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5500000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4500000	usd
CY2023	sls	Proceeds From Issuance Of Common Stock And Common Stock Warrants ProceedsFromIssuanceOfCommonStockAndCommonStockWarrants	21936000	usd
CY2022	sls	Proceeds From Issuance Of Common Stock And Common Stock Warrants ProceedsFromIssuanceOfCommonStockAndCommonStockWarrants	22946000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	289000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1048000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	14000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	107000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	85000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	31000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22315000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24079000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14595000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4230000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17225000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21455000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2630000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17225000	usd
CY2023	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	525000	usd
CY2022	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	317000	usd
CY2023Q4	sls	Acquired In Process Research And Development Payable AcquiredInProcessResearchAndDevelopmentPayable	0	usd
CY2022Q4	sls	Acquired In Process Research And Development Payable AcquiredInProcessResearchAndDevelopmentPayable	5500000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	368000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	449000	usd
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	103000	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-217200000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-37300000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31400000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2500000	usd
CY2023	sls	Collaborative Arrangement Upfront Fee And Milestone Payments CollaborativeArrangementUpfrontFeeAndMilestonePayments	10500000	usd
CY2023	sls	Research And Development Arrangement Potential Milestone Payments To Be Received ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived	191500000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, carrying value of goodwill, and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</span></div>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions, the balances of which frequently exceed federally insured limits.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the financial institutions with whom we do business were to be placed into receivership, we may be unable to access to the cash we have on deposit with such institutions.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2530000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17125000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2630000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17225000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1900000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1900000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17799000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6436000	shares
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023Q4	sls	Prepaid Research And Development PrepaidResearchAndDevelopment	399000	usd
CY2022Q4	sls	Prepaid Research And Development PrepaidResearchAndDevelopment	184000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	87000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	219000	usd
CY2023Q4	sls	Prepaid Professional Services PrepaidProfessionalServices	56000	usd
CY2022Q4	sls	Prepaid Professional Services PrepaidProfessionalServices	82000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	0	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	46000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	542000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531000	usd
CY2023Q4	sls	Contract Research Payable ContractResearchPayable	5672000	usd
CY2022Q4	sls	Contract Research Payable ContractResearchPayable	4509000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1493000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1439000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	443000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	338000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	42000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7650000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6286000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.130
CY2023	sls	Operating Lease Remaining Lease Term OperatingLeaseRemainingLeaseTerm	P1Y9M
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	500000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	533000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	477000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1010000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	104000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	906000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15854000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1607000	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	21933000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5141000	shares
CY2023	sls	Class Of Warrant Or Right Grants ClassOfWarrantOrRightGrants	11424000	shares
CY2023	sls	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	566000	shares
CY2023	sls	Classof Warrantor Right Canceled Or Expired ClassofWarrantorRightCanceledOrExpired	145000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15854000	shares
CY2021Q4	sls	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	40000	usd
CY2022	sls	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-36000	usd
CY2022Q4	sls	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	4000	usd
CY2023	sls	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-4000	usd
CY2023Q4	sls	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	0	usd
CY2020Q4	sls	Research And Development Arrangement Cash Payment Received ResearchAndDevelopmentArrangementCashPaymentReceived	7500000	usd
CY2020Q4	sls	Research And Development Arrangement Potential Milestone Payments To Be Received Maximum ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum	194500000	usd
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	9500000	usd
CY2020Q4	sls	Research And Development Arrangement Cash Payment Received ResearchAndDevelopmentArrangementCashPaymentReceived	7500000	usd
CY2020Q4	sls	Research And Development Arrangement Milestones Probable Of Being Achieved ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved	2000000	usd
CY2022Q1	sls	Proceeds From Research And Development Arrangement Milestone Payments ProceedsFromResearchAndDevelopmentArrangementMilestonePayments	1000000	usd
CY2023Q4	sls	Research And Development Arrangement Potential Milestone Payments To Be Received ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived	191500000	usd
CY2023	sls	Contract With Customer Liability New Contract Revenue Recognized ContractWithCustomerLiabilityNewContractRevenueRecognized	0	usd
CY2022	sls	Contract With Customer Liability New Contract Revenue Recognized ContractWithCustomerLiabilityNewContractRevenueRecognized	1000000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	100000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2094000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1726000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0378
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0196
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.2777
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.88
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.52
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2900000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	534000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.09
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	546000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.01
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	40000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.17
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.57
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	682000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.20
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	115000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.68
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1607000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.92
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	sls	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	639000	shares
CY2023Q4	sls	Sharebased Compensation Arrangementby Sharebased Payment Award Options Vested And Exercisable Weighted Average Exercise Price SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice	8.78
CY2023	sls	Sharebased Compensation Arrangementby Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm	P7Y3M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	usd
CY2023Q4	sls	Closing Price Of Common Stock ClosingPriceOfCommonStock	1.06
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.119
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.065
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.087
CY2023	sls	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.004
CY2022	sls	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.002
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-10116000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-17825000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-27224000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-23476000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37340000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-41301000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12220000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10529000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	613000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	229000	usd
CY2023Q4	sls	Deferred Tax Assets Licensing Deduction Deferral DeferredTaxAssetsLicensingDeductionDeferral	3911000	usd
CY2022Q4	sls	Deferred Tax Assets Licensing Deduction Deferral DeferredTaxAssetsLicensingDeductionDeferral	4503000	usd
CY2023Q4	sls	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	194000	usd
CY2022Q4	sls	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	198000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	1755000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	765000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	297000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	282000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	18990000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16506000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	18806000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16322000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	184000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	184000	usd
CY2023Q4	sls	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	184000	usd
CY2022Q4	sls	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	184000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	184000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	184000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	184000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	184000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	184000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	184000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.001
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.153
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2500000	usd
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	139000	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	129000	usd
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001390478-24-000004-index-headers.html	Edgar Link	pending
0001390478-24-000004-index.html	Edgar Link	pending
0001390478-24-000004.txt	Edgar Link	pending
0001390478-24-000004-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sls-20231231.htm	Edgar Link	pending
sls-20231231.xsd	Edgar Link	pending
sls-20231231ex1049.htm	Edgar Link	pending
sls-20231231ex1050.htm	Edgar Link	pending
sls-20231231ex1051.htm	Edgar Link	pending
sls-20231231_g1.jpg	Edgar Link	pending
sls-20231231_g2.jpg	Edgar Link	pending
sls-20231231_g3.jpg	Edgar Link	pending
sls-20231231_g4.jpg	Edgar Link	pending
sls-20231231_g5.jpg	Edgar Link	pending
sls-20231231_g6.jpg	Edgar Link	pending
sls-20231231_g7.jpg	Edgar Link	pending
sls-20231231_g8.jpg	Edgar Link	pending
sls-20231231_g9.jpg	Edgar Link	pending
sls20231231ex211nextgen.htm	Edgar Link	pending
sls20231231ex231nextgen.htm	Edgar Link	pending
sls20231231ex311nextgen.htm	Edgar Link	pending
sls20231231ex312nextgen.htm	Edgar Link	pending
sls20231231ex321nextgen.htm	Edgar Link	pending
sls-20231231_def.xml	Edgar Link	unprocessable
sls-20231231_lab.xml	Edgar Link	unprocessable
sls-20231231_pre.xml	Edgar Link	unprocessable
sls-20231231_htm.xml	Edgar Link	completed
sls20231231ex97.htm	Edgar Link	pending
sls-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2024 Q1 Form 10-K Financial Statement

#000139047824000004 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2024 Q1 Form 10-K Financial Statement

#000139047824000004 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls